Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iscalimab vs Standard of Care in Liver Transplant (CONTRAIL I)
NCT03781414Phase 2Terminated
- Sponsor
- Novartis
- Start
- Oct 2019
- Primary completion
- Apr 2023
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
A Phase 2 trial of iscalimab in Liver transplant rejection, sponsored by Novartis. Started Oct 2019; status: terminated.
02
Drugs
iscalimab
03
Conditions
Liver transplant rejection
Beyond the preview
Go deeper on NCT03781414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03781414.